Financials data is unavailable for this security.
View more
Year on year Vir Biotechnology Inc 's revenues fell -94.67% from 1.62bn to 86.18m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 515.84m to a loss of 615.06m.
| Gross margin | 98.80% |
|---|---|
| Net profit margin | -612.40% |
| Operating margin | -715.62% |
| Return on assets | -24.69% |
|---|---|
| Return on equity | -29.78% |
| Return on investment | -26.90% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Vir Biotechnology Inc fell by 606.68m. However, Cash Flow from Investing totalled 164.63m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 778.79m for operations while cash generated from financing totalled 7.48m.
| Cash flow per share | -3.35 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 10.50 |
|---|---|
| Tangible book value per share | 10.23 |
More ▼
Balance sheet in USDView more
| Current ratio | 12.51 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
